AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27502721
Drug: Adjusted BSA
RxNorm normalized name: Fmlt bsasm h
DrugBank: Honokiol (DB19283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted BSA chemotherapy
Trial: 27502721
Drug: Obese patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese patients receiving full-dose chemotherapy
Trial: 27502721
Drug: Obese patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese patients receiving adjusted BSA chemotherapy
Trial: 24060107
Drug: tDCS combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS combined with sertraline
Trial: 19747986
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with PEG interferon alfa-2b 3.0 mcg/kg/wk for 12 weeks followed by PEG interferon alfa-2b 1.5 mcg/kg/wk for 36 weeks and ribavirin 13 +/- 2 mg/kg daily for 48 weeks
Trial: 19747986
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) with PEG interferon alfa-2b 1.5 mcg/kg weekly for 48 weeks and ribavirin 13 +/- 2 mg/kg daily for 48 weeks
Trial: 19747986
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy in patients weighing more than 85 kg
Trial: 15950851
Drug: Droperidol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (50 mug) with morphine (1 mg) via PCA
Trial: 15950851
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 mg morphine via PCA)
Trial: 12730085
Drug: Transdermal 17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐estradiol (E2) 50 microg (tE2 group, n=33)
Trial: 12730085
Drug: Oral E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2 1 mg (oE2 group, n=37)
Trial: 12730085
Drug: Oral E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2 1 mg combined with gestodene 25 microg (oE2+G group, n=33)
Trial: 10493334
Drug: PNCRM7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNCRM7 vaccine
Trial: 10493334
Drug: PNCRM7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNCRM7 vaccine with hepatitis B vaccine
Trial: 10493334
Drug: PNCRM7 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNCRM7 vaccine with DTaP and HbOC
Trial: 24131861
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behaviour therapy
Trial: 24131861
Drug: Optimised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised treatment as usual
Trial: 29567358
Drug: Topical VTP‐38543
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical VTP‐38543 (0.05%, 0.15%, and 1.0%) applied twice daily for 28 days
Trial: 26611780
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (n = 55) ingested daily 9 log10 colony‐forming units of L. salivarius PS2 from approximately week 30 of pregnancy until delivery
Trial: 25202937
Drug: Segmental epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segmental epidural steroid injection (80 mg of triamcinolone)
Trial: 22227611
Drug: Told alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Told alcohol (0.4 g/kg ethanol)
Trial: 22227611
Drug: Told placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Told placebo (0.0 g/kg ethanol)
Trial: 12534378
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 50 mg
Trial: 1574244
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide (1,500-2,500 mg/m2)
Trial: 1574244
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide (2,000 mg/m2 or greater)
Trial: 1574244
Drug: High-dose etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose etoposide (1,500 mg/m2)
Trial: 2864849
Drug: Esmolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (mean dosage 142 +/- 100 micrograms/kg/min, range 50 to 300 micrograms/kg/min)
Trial: 2864849
Drug: Nitroprusside (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside (mean dose 1.6 +/- 1.3 micrograms/kg/min, range 0.5 to 2.75 micrograms/kg/min)
Trial: 29462224
Drug: Tavaborole 5%
RxNorm normalized name: TAVABOROLE 5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tavaborole 5% topical treatment
Trial: 27108476
Drug: Immediate non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate non-surgical periodontal therapy
Trial: 27108476
Drug: Delayed non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed non-surgical periodontal therapy (Control)
Trial: 24675394
Drug: Standard AI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AI treatment plus educational materials (EMs)
Trial: 24675394
Drug: Standard AI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AI treatment
Trial: 18456568
Drug: rifaximin therapy
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rifaximin therapy (1200 mg/day for 10 days)
Trial: 18456568
Drug: rifaximin therapy
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rifaximin therapy (after placebo)
Trial: 18456568
Drug: rifaximin therapy
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rifaximin therapy (for patients with negative BTs)
Trial: 16181529
Drug: CHD Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHD Capsules (CHDC)
Trial: 16181529
Drug: Compound Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Prescription Danshen Droplet Pills (CPDDP)
Trial: 10381807
Drug: Codeine 120
RxNorm normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 120 mg with placebo
Trial: 10381807
Drug: Codeine 120
RxNorm normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 120 mg with quinidine 100 mg
Trial: 8682138
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg bd
Trial: 8682138
Drug: Nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine SR 20 mg bd
Trial: 1986659
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) - 20-25 micrograms/kg
Trial: 1986659
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of meperidine (1.5 mg/kg), diazepam (0.2 mg/kg), and atropine (0.02 mg/kg)
Trial: 1986659
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of meperidine, diazepam, and atropine
Trial: 28902580
Drug: PFO closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PFO closure plus antiplatelet therapy
Trial: 27266281
Drug: Nebulised magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised magnesium sulphate (MS) 151 mg/dose with ipratropium bromide (IB) 500 µg
Trial: 27266281
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with ipratropium bromide (IB) 500 µg
Trial: 7943519
Drug: Ligament augmentation
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligament augmentation device
Trial: 12435652
Drug: No ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ligament augmentation device (control)
Trial: 1940965
Drug: CDP‐choline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP‐choline (1 g)
Trial: 7038950
Drug: Doxapram hydrochloride
RxNorm normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxapram hydrochloride infusions
Trial: 31048443
Drug: Intranasal inoculation
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal inoculation of genetically modified N. lactamica expressing the meningococcal antigen NadA
Trial: 30049309
Drug: Etripamil nasal
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil nasal spray (various doses)
Trial: 30049309
Drug: Etripamil nasal
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil nasal spray (highest dose)
Trial: 22104564
Drug: Adjuvant interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon alfa‐2b (IFNα‐2b) therapy for 53 weeks
Trial: 22104564
Drug: Adjuvant interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon alfa‐2b (IFNα‐2b) therapy
Trial: 19156973
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg kg(‐1) rocuronium
Trial: 6385607
Drug: Mucosolvan (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosolvan (60 mg X 2 daily)
Trial: 28508561
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac 4 h before IVI and topical diclofenac 45 min before IVI
Trial: 28508561
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac 45 min before IVI
Trial: 28508561
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (oral and topical diclofenac)
Trial: 25382404
Drug: Pleurotus ostreatus
RxNorm normalized name: Pleurotus ostreatus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleurotus ostreatus (P.o) and Pleurotus cystidiosus (P.c) at a dose of 50 mg/kg/body weight
Trial: 21849415
Drug: Nicotine mouth
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mouth spray 4 mg
Trial: 21849415
Drug: Nicotine mouth
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mouth spray 2 mg
Trial: 21849415
Drug: Nicotine mouth
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine mouth spray 1 mg
Trial: 21849415
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge 4 mg
Trial: 21849415
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum 4 mg
Trial: 16332282
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus self-help
Trial: 8057661
Drug: Intensified protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified protocol with high-dose chemotherapy and autologous or allogeneic bone marrow transplantation
Trial: 8057661
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment from previous trials
Trial: 2923766
Drug: Plain 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain 0.5% bupivacaine 3 ml
Trial: 2923766
Drug: Plain 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain 0.25% bupivacaine 6 ml
Trial: 29984832
Drug: Novel chocolate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel chocolate-based tablet formulation of midazolam (0.5 mg.kg−1)
Trial: 29984832
Drug: Intravenous solution
RxNorm normalized name: Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution of midazolam (0.5 mg.kg−1)
Trial: 29984832
Drug: Novel chocolate-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel chocolate-based tablet formulation of midazolam
Trial: 19255206
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (28 knees)
Trial: 19255206
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (36 knees)
Trial: 12970272
Drug: 30 mCi
RxNorm normalized name: Xofigo 30 MCI/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mCi (131)I with rhTSH stimulation after stopping L-T4
Trial: 12970272
Drug: 30 mCi
RxNorm normalized name: Xofigo 30 MCI/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mCi (131)I in hypothyroid state after L-T4 withdrawal
Trial: 12970272
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving rhTSH without stopping L-T4
Trial: 9258101
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative subcutaneous heparin
Trial: 2438924
Drug: Pirmenol hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirmenol hydrochloride 300 mg/day
Trial: 2438924
Drug: Pirmenol hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirmenol hydrochloride 400 mg/day
Trial: 22399700
Drug: Daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exercise (30 min of cycling exercise at 50% maximal workload capacity)
Trial: 12552940
Drug: Early intensification
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intensification chemotherapy
Trial: 353680
Drug: Active medications
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medications
Trial: 353680
Drug: Placebo medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medications
Trial: 27910156
Drug: Ixekizumab Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q4W (80 mg every 4 weeks after a 160 mg starting dose)
Trial: 27910156
Drug: Ixekizumab Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab Q2W (80 mg every 2 weeks after a 160 mg starting dose)
Trial: 25367222
Drug: BF‐FES +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF‐FES + mirror therapy
Trial: 25367222
Drug: FES +
RxNorm normalized name: Ferric Ethylenediamine Tetraacetic Acid (Ferric EDTA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES + mirror therapy
Trial: 25367222
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional physical therapy program)
Trial: 23794414
Drug: Tolvaptan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (5 to 240 mg)
Trial: 12927001
Drug: Venlafaxine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (up to 150 mg/day)
Trial: 7645699
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen administration (up to 6 l.min‐1)
Trial: 2144019
Drug: Ondansetron 5
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 5 mg/m2 IV (group A)
Trial: 2144019
Drug: Ondansetron 3
RxNorm normalized name: ondansetron 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 3 mg/m2 IV (group B)
Trial: 7009593
Drug: Alprazolam (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (2.2 mg daily for 21 days)
Trial: 7009593
Drug: Diazepam (20.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (20.2 mg daily for 21 days)
Trial: 31387097
Drug: Molidustat in
RxNorm normalized name: Molidustat
DrugBank: Molidustat (DB15642)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molidustat in treatment-naïve patients not on dialysis
Trial: 28470100
Drug: Dexmedetomidine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.25 µg/kg (D1)
Trial: 28470100
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 µg/kg (D2)
Trial: 28470100
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 µg/kg (D3)
Trial: 21849729
Drug: DD current
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DD current therapy
Trial: 16278260
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) plus testosterone (T) implants
Trial: 16278260
Drug: Testosterone (T)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) implants alone
Trial: 12921985
Drug: Homocysteine concentration
RxNorm normalized name: mecysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homocysteine concentration >12 micromol/l
Trial: 12921985
Drug: Erythrocyte S-adenosylmethionine
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythrocyte S-adenosylmethionine concentration >4000 nmol/l
Trial: 8677737
Drug: G‐CSF/IL‐3 combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF/IL‐3 combination
Trial: 20214527
Drug: Lapatinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib monotherapy
Trial: 12488257
Drug: New topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New topical cysteamine formulation
Trial: 12488257
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of topical cysteamine
Trial: 11817492
Drug: Opioid taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid taper algorithm (phase 2)
Trial: 7258124
Drug: Commercial multivitamin‐multimineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial multivitamin‐multimineral supplement
Trial: 24768161
Drug: Prenatal drug
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal drug exposure (PDE)
Trial: 24768161
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and perceived peer drug use
Trial: 23975326
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g oil (rapeseed) with 3 μm droplet size
Trial: 23975326
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g oil (rapeseed) with 0.1 μm droplet size
Trial: 23975326
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g oil (rapeseed) with 3 μm droplet size
Trial: 23975326
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g oil (rapeseed) with 0.1 μm droplet size
Trial: 16040729
Drug: 38% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride (SDF) solution applied every 6 months for 36 months
Trial: 16040729
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SDF treatment)
Trial: 8470424
Drug: NIB-14 vaccine
RxNorm normalized name: pneumococcal capsular polysaccharide type 14 vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide antigen (DB10332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIB-14 vaccine
Trial: 8470424
Drug: NIB-17 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIB-17 vaccine
Trial: 8470424
Drug: Cross-reactive antibodies
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-reactive antibodies
Trial: 2879960
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg twice daily) during intravenous clorazepate administration
Trial: 23500276
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial appendage closure device (warfarin naive subgroup)
Trial: 23500276
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (warfarin naive subgroup)
Trial: 22076546
Drug: Daclizumab monotherapy
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab monotherapy for 54 weeks
Trial: 16772027
Drug: PD on
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD on medication